InBioNET Submits Market Registration for Human Recombinant Interleukin-2

Upon completion of the domestic phase II clinical trial of interleukin-2 (product name: Geneleukin), a biopharmaceutical anticancer agent, InBioNET Inc. announced last week that it has submitted a market registration request for Geneleukin to the Korea Food and Drug Administration (KFDA).

According to the company, Geneleukin, a human recombinant interleukin-2, is currently being applied for ...